ReviewCurrent allergy and asthma reports2020
Peanut Oral Immunotherapy: a Current Perspective.
Review in Current allergy and asthma reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05163574 (Induction of Sustained Unresponsiveness to Peanuts Using High- and Low-dose Peanut Oral Immunotherapy - Evaluation of Efficacy and Safety), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Induction of Sustained Unresponsiveness to Peanuts Using High- and Low-dose Peanut Oral Immunotherapy - Evaluation of Efficacy and Safety
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Peanut allergy oral immunotherapy drives single-cell multi-omic changes in peanut-reactive T cells associated with sustained unresponsiveness.Nature immunology · 2025Trial
- CD8Nature communications · 2022Trial
- Trial
- Egg desensitization is achieved effectively and safely through a low maintenance dose protocol.The journal of allergy and clinical immunology. Global · 2025Article
- The Relationship Between Asthma and Food Allergies in Children.Children (Basel, Switzerland) · 2024Review
- A review of sublingual immunotherapy for treatment of peanut allergy.Journal of food allergy · 2024Article
- The Future of Food Allergy Management: Advancements in Therapies.Current allergy and asthma reports · 2024Review
- Peanut Allergy and Component-Resolved Diagnostics Possibilities-What Are the Benefits?Nutrients · 2023Review
- Review
- A novel peanut allergy immunotherapy: Plant-based enveloped Ara h 2 Bioparticles activate dendritic cells and polarize T cell responses to Th1.The World Allergy Organization journal · 2023Article
- Peanut allergen inhibition prevents anaphylaxis in a humanized mouse model.Science translational medicine · 2023Article
- Dose and route of administration determine the efficacy of prophylactic immunotherapy for peanut allergy in a Brown Norway rat model.Frontiers in immunology · 2023Article
- IgE and IgG4 epitopes of the peanut allergens shift following oral immunotherapy.Frontiers in allergy · 2023Article
- The rationale for development of ligelizumab in food allergy.The World Allergy Organization journal · 2022Review
- Qualitative interviews to understand health care providers' experiences of prescribing licensed peanut oral immunotherapy.BMC research notes · 2022Article
- Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- Angled Insertion of Microneedles for Targeted Antigen Delivery to the Epidermis.Pharmaceutics · 2022Article
- Use of a Liver-targeting Nanoparticle Platform to Intervene in Peanut-induced anaphylaxis through delivery of an Ara h2 T-cell Epitope.Nano today · 2022Article
- Peanut oral immunotherapy: current trends in clinical trials.Immunotherapy advances · 2022Review
- Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?Frontiers in allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewPeanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments. RECENT
findingsThe latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions. Future research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.